The Opioid Epidemic in Philadelphia

Implementation of the

Mayor’s Task Force Recommendations

October 10, 2018
On May 19, 2017, Mayor James Kenney’s Task Force to Combat the Opioid Epidemic in Philadelphia released its final report and recommendations. The 18 recommendations – organized by Prevention and Education, Treatment, Overdose Prevention and Criminal Justice – provide actionable, evidence-based steps the City and its partners can take to reduce the harmful effects of opioids in our community.

The importance of these recommendations cannot be overstated. This epidemic continues to claim Philadelphians’ lives every day. Over 1,200 people died from drug overdoses in Philadelphia in 2017, an increase from 907 deaths the year prior and more than three times the number of homicides.¹ Thousands of Philadelphia residents had non-fatal overdoses, while an estimated 469,000 people used a prescription opioid in the past year.² Addressing the crisis has been, and continues to be, one of the City’s top priorities.

The Task Force resulted in new targeted efforts and opportunities, and implementation of the recommendations is underway across the city. Since the final report was released, progress has been made on all 18 recommendations and the City has provided quarterly updates to the Mayor’s Commission on Addiction and Recovery, the group designated to provide feedback to and oversight of the City’s efforts.

This report summarizes the progress made towards full implementation of the recommendations. Previous quarterly reports made to the Mayor’s Commission on Addiction and Recovery can be found at: http://www.phila.gov/opioids

¹ Medical Examiner’s Office, Philadelphia Department of Public Health.
### Mayor’s Task Force Final Recommendations and Progress Highlights since June 2018

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Progress Highlight</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PREVENTION AND EDUCATION</strong></td>
<td>Two waves of “Don’t Take the Risk” (<a href="http://www.donttaketherisk.com">www.donttaketherisk.com</a>) were shown on TV and social media.</td>
</tr>
<tr>
<td>Conduct a consumer directed media campaign about opioid risks</td>
<td>A campaign encouraging people to carry naloxone was recently on billboards, bus shelters and public transit, and on social media.</td>
</tr>
<tr>
<td>Conduct a public education campaign about naloxone</td>
<td>DBHIDS and PDPH are planning a medication-assisted treatment (MAT) media campaign focusing on buprenorphine targeting adults (25-44 years of age) who are considering seeking treatment.</td>
</tr>
<tr>
<td>Destigmatize opioid use disorder and its treatment</td>
<td>The Health Department mailed letters to nearly 1,000 dentists in Philadelphia, informing them that several non-opioid pain medications are more effective than opioids at treating acute dental pain.</td>
</tr>
<tr>
<td>Improve health care professional education</td>
<td>Beginning September 2018, public and private health insurers adopted more uniform prior authorization policies to reduce the overprescribing of prescription opioids.</td>
</tr>
<tr>
<td>Establish insurance policies that support safer opioid prescribing and treatment</td>
<td>MAT capacity and provision continues to increase with more than 3,000 slots currently available. DBHIDS issued three policies to its provider network to increase and incentivize education, individual choice, and availability of MAT. MAT policies went into effect as of 7/1/2018 and will be implemented through 1/1/2020. MAT inductions are occurring in three Emergency Departments.</td>
</tr>
<tr>
<td><strong>TREATMENT</strong></td>
<td>The web-based treatment capacity database is being finalized. Temple Episcopal Crisis Response Center has hired staff and received approval from the Pennsylvania Dept. of Health to begin renovations that will expand its capacity to engage, assess, and treat individuals with Opioid Use Disorder (OUD). Recent bulletins and policies issued to the DBHIDS provider network will increase access by removing multiple barriers. NET Access Point is now accepting members with a full range of substance use disorders and withdrawal symptoms for assessment, stabilization, and referral to appropriate level of care with warm hand-off.</td>
</tr>
<tr>
<td>Increase the provision of medication-assisted treatment (MAT)</td>
<td>A pilot to incorporate withdrawal management into the Journey of Hope Project has been approved. The program hired a medical director and is pending a DEA license and physical modifications. DBHIDS is exploring moving forward with an ambulatory stabilization program at University of Pennsylvania Health System. MAT policies and American Society of Addiction Medicine (ASAM) Criteria implementation will be effective 1/2020, which will recognize and increase availability of withdrawal management.</td>
</tr>
<tr>
<td>Expand treatment access and capacity</td>
<td>Discussions have begun with multiple hospitals to support warm handoffs as a part of a new Pay for Performance Initiative. An initial meeting was held with in-network behavioral health providers in the Kensington area to facilitate warm handoffs and foster referral relationships. PRO-ACT has been approved by the State as a supplemental service provider for Certified Recovery Specialist (CRS) services, making them eligible for Medicaid reimbursement. Once finalized, the ROSE Project can expand to other hospitals and allow DBHIDS to deploy CRS in the community targeting individuals presenting to acute medical settings with opioid related issues.</td>
</tr>
<tr>
<td>Embed withdrawal management into all levels of care, with an emphasis on recovery initiation</td>
<td>Halfway House capacity will be increased with 3 new specialty programs serving transition age youth, women with children, and Spanish speaking women. First Step Staffing has secured full-time positions for 46 individuals with a history of homelessness, substance use, and/or incarceration. The DBHIDS Funded Recovery House Network was expanded with the addition of One Day at a Time (ODAAT) 2, a 40 bed Recovery House for men and women.</td>
</tr>
</tbody>
</table>
### INvolvement of the Criminal Justice System

| Expand the court’s capacity for diversion to treatment | The Office of Criminal Justice, DBH, the First Judicial District, the District Attorney’s Office, and the Defender Association are examining existing court-based diversion programs to determine if expansion or creation of a new program can most effectively address opioid use disorder. |
| Expand enforcement capacity in key areas | Forty-eight police officers on bikes are dedicated to the East Police Division. Philadelphia Police also conducted four large enforcement initiatives in the East Police Division in 2017, seizing over $1M worth of drugs in areas with high drug sales. This year one enforcement initiative has been conducted in June resulting in 166 total arrests. A second initiative occurred October 3-6, 2018. The Real Time Crime Center maintains records of overdose incidents in order to determine surges in overdoses and deploy law enforcement resources appropriately. |
| Provide substance use disorder assessment and treatment in the Philadelphia Department of Prisons (PDP) | PDP began offering buprenorphine in the women’s jail in July of this year and expanded to all PDP facilities in September. Approximately 90% of opioid-addicted patients not maintained on methadone choose to receive buprenorphine. All inmates receiving Medication Assisted Treatment are also offered cognitive behavioral therapy. PDP is offering to enroll inmates in Medical Assistance and for sentenced individuals is making post-release appointments with community MAT providers. In addition, all inmates and visitors are educated about the risk of overdose, the use of naloxone and where to obtain it. All inmates receive the Commonwealth’s standing order for naloxone upon release, while inmates whose withdrawal is medically managed are offered a kit of naloxone when released (~6,000 annually). |

### OVERdose Prevention and Harm Reduction

| Expand naloxone availability | Since the Task Force, the City has identified new partners to distribute naloxone to high-risk populations. It has also distributed over 57,000 doses of naloxone and trained nearly 2,000 individuals in overdose education and naloxone use. Information about naloxone can be found at http://www.phillynaloxone.com. |
| Further explore overdose prevention sites | The City has identified Safehouse, a nonprofit organization, that will provide overdose prevention services, including operating a medically supervised consumption room. The City is assisting Safehouse in finding funding and securing a location, as well as addressing the legal issues and meeting with stakeholders and community members. |
| Establish a coordinated rapid response to “outbreaks” | A city-wide rapid response protocol has been drafted by PDPH, DBHIDS and PPD. While the protocol was implemented successfully during the September 21-22 outbreak involving synthetic cannabinoids, further refinements continue to be made. |
| Address homelessness among opioid users | The City is working to address homelessness among people who use drugs by opening emergency shelters, closing encampments and facilitating access to housing for people in the encampments, and deploying additional outreach teams to help homeless individuals. 50 individuals experiencing homelessness from Journey of Hope and Safe Haven programs have been matched to supportive housing for people with disabilities (Section 811 subsidies). 20 new Shallow Rent Subsidies are available for individuals experiencing homelessness from Journey of Hope, Safe Havens, and DBH-Funded Recovery Houses. |

Incentivize providers to enhance the quality of substance abuse disorder screening, treatment, and workforce | DBHIDS has launched a monthly MAT Learning Collaborative which will run in accordance with the MAT policies to be implemented 1/2020. DBHIDS also hosted training for the provider network on Opioid Use Disorder: Evidence-Based Treatment Models for MAT and Integrated Care for Co-Occurring Chronic Pain. In partnership with Quality Insights, DBHIDS provided three continuing education modules on the Pennsylvania Drug Monitoring Program (PDMP) across two days which were open to all Philadelphia prescribers and included “Approaches to Address Patients’ Substance Use Disorder.” |
Graphs of Core Task Force Metrics from the Opioid Misuse and Overdose Report, Philadelphia, PA (updated October 2018)

Additional data can be found on the City’s opioid website: http://www.phila.gov/opioids

---

**PRESCRIPTION OPIOIDS**

**Sale of Selected Prescription Opioids, Philadelphia, 2001 - 2017**

- OXYCODONE (*1.5)
- HYDROCODONE (*1)
- MORPHINE
- FENTANYL BASE (*75)
- TOTAL Morphine Equivalents

**Number of opioid prescriptions written for Phila residents (excluding buprenorphine), 2016 Q3 - 2018 Q1**
Philadelphia DBHIDS In-Network
Medication Assisted Treatment Capacity, as of
9/28/2018

Total DBHIDS In-Network MAT Program Capacity (any medication) = 12,836
NALOXONE

Naloxone – doses distributed

Since July 1, 2017, the City has distributed **57,716 doses of naloxone** to law enforcement agencies and other organizations:

- **Providers and Community Organizations**: 44,194 doses
- **Criminal justice organizations**: 9,722 doses
- **EMS, Philadelphia Police Department and SEPTA Police**: 3,800 doses

Naloxone – doses administered by first responders

![Graph](image-url)
Number of Opioid Related Deaths with Specific Drug Present by Quarter, 2010 – 2018Q1

Number of Drug-Related Overdose Deaths by Quarter, 2010 – 2018Q1

* 2018 Q2 data have not been finalized
Number of ED Visits for Drug-Related Overdoses by Quarter, 2010 – 2018Q2
ACCESSING TREATMENT

CALL CBH MEMBER SERVICES

Call 1-888-545-2600 24/7 365 days/year to gain assistance with accessing publicly funded Substance Use Disorder (SUD) treatment and services.

Community Behavioral Health (CBH) manages behavioral health services for Philadelphia residents enrolled in Medicaid and can also assist you if you are uninsured or not sure of your insurance coverage.

Other common Philadelphia insurers:
Medicare: 1-800-MEDICARE (1-800-633-4227)
Magellan Healthcare: 1-800-688-1911
Behavioral Health Special Initiative (BHSI): 215-546-1200

WHAT TO EXPECT

Treatment Begins with an Assessment:
Addiction professionals use criteria to help determine the setting and intensity that will help you achieve the best outcomes. The Pennsylvania Client Placement Criteria (PCPC) and American Society of Addiction Medicine (ASAM) Criteria are the criteria most frequently used to determine medical necessity.

Residential and Hospital Treatment:
If the evaluator determines that residential treatment would help achieve the best results for you, they will contact your insurer to obtain approval to move forward with treatment and help you find and get to a facility that can provide the rehabilitation, detoxification/withdrawal management, or hospital based treatment that is appropriate.

Community Based and Outpatient Treatment:
Many people can and do recover from their addiction with the support of an outpatient treatment program. For outpatient treatment, contacting your insurer is the best way to find a convenient option.

- There are three levels of outpatient treatment:
  - traditional outpatient
  - intensive outpatient
  - partial hospitalization programs.

These programs combine counseling with medication to help individuals reduce symptoms and triggers of addiction, while strengthening a person’s ability to cope with cravings. The main difference between levels is the intensity and frequency of treatment visits. If you are currently enrolled in a community treatment program, they can also assess you for additional needs, such as residential treatment. See the attached list of community treatment programs.
WHERE TO GO FOR AN ASSESSMENT

NET Access Point 844-533-8200 or 215-408-4987
499 North 5th Street, Suite B, Philadelphia, PA 19123
www.netcenters.org
Open 24 hours/day and 7 days/week. Offering Buprenorphine & Vivitrol Induction

Crisis Response Centers
  Friends Hospital 4641 Roosevelt Blvd. (215) 831-2600
  Mercy Hospital 501 S. 54th St. (215) 748-9525
  Einstein Medical Center 5501 Old York Rd. (215) 951-8300
  Pennsylvania Hospital (Hall Mercer) 800 Spruce St. (215) 829-5433
  Temple/Episcopal Hospital 100 E. Lehigh Ave. (215) 707-2577
  Philadelphia Children’s Crisis Response Center
  3300 Henry Ave. Falls Two Building, 3rd Floor. (215) 878-2600

Pathways to Recovery (PHMC) Partial Hospitalization
  2301 East Allegheny Avenue, Philadelphia, PA 19134
  215-731-2404 - English/Spanish. Buprenorphine & Vivitrol Induction

Nearest Substance Use Disorder Treatment Provider
See attached list of community treatment programs

If you are uninsured, covered by Medicaid/CBH, or not sure of your insurance coverage, contact CBH Member Services at 1-888-545-2600 24/7, 365 days/year to gain assistance with accessing publicly funded SUD treatment and services.

In the event of a medical emergency, please call 911 and present to the nearest emergency room.
<table>
<thead>
<tr>
<th>Provider &amp; Contact Info</th>
<th>MAT</th>
<th>Additional Information</th>
</tr>
</thead>
</table>
| **ADDITION MEDICINE AND HEALTH ADVOCATES (AMHA)**
928 MARKET ST, 19107 (215)923-4204 | MMT induction | IOP/ OP English/ Spanish; child care on site |
| **ASOCIACION PUERTORRIQUEÑOS EN MARCHA (APM)**
4301 RISING SUN AVE, PHILA, 19140 (267)296-7200 | Buprenorphine induction | IOP/ OP; MH Tx on-site English/ Spanish |
| **BELMONT BEHAVIORAL HOSPITAL**
4200 MONUMENT ROAD, 19131 (877)418-7923 | Buprenorphine maintenance Vivitrol | IOP/ OP; MH Tx on-site English/ Spanish; child care on site |
| **CHANCES- PHILA HEALTH MGMT CORP (PHMC)**
1200 CALLOWHILL ST, SUITE 102, 19123 (215)825-8220 | Buprenorphine induction Vivitrol | IOP / OP English; females only, child care on site |
| **COMHAR**
2055 E. ALLEGHENY AVE, 19134 (215)427-5800 | Buprenorphine induction | OP; MH Tx on-site English/ Spanish |
| **THE CONSORTIUM**
451 S. UNIVERSITY AVE, 19104 (215)967-2130 | MMT induction Vivitrol | IOP / OP; MH Tx on-site English/ Spanish |
| **DREXEL MEDICINE CARING TOGETHER CLINIC**
4700 WISSAHICKON AVE, 19144 (215)967-2130 | Buprenorphine/Vivitrol maintenance | OP English; females only, child care on site |
| **GAUDENZIA OUTREACH I**
1306 SPRING GARDEN ST, 19123 215-238-2150 | Vivitrol | IOP / OP; MH Tx on-site English/ Spanish |
| **GAUDENZIA-DRC**
3200 HENRY AVE, 19129 215-991-9700 |  | IOP / OP English |
| **INTERIM HOUSE, INC. - PHMC**
333 W. UPSAL ST, 19139 215-849-4606 | Buprenorphine induction Vivitrol | IOP / OP; MH Tx on-site English/ Spanish |
| **JEVS HUMAN SERVICES - ACT I**
5820 OLD YORK ROAD, 19141 | MMT induction | IOP / OP English/ Spanish |
| **JEVS HUMAN SERVICES - ACT II**
1745 N. 4TH ST, 19122 (215)236-0100 | MMT induction | IOP / OP English/ Spanish |
| **JOHN F. KENNEDY BEHAVIORAL HEALTH CENTER (JFK)**
907 N. BROAD ST, 19123 (215)567-2469 | MMT induction | OP; MH Tx on-site English |
| **KENSINGTON HOSPITAL**
136 DIAMOND ST, 19122 (215)426-8100 | MMT induction | OP English |
| **MERAKEY BEHAVIORAL HEALTH**
5000 PARKSIDE AVE, 19131 215-879-6116 | Buprenorphine induction | IOP / OP; MH Tx on-site English |
| **MERAKEY BEHAVIORAL HEALTH**
5429 GERMANTOWN AVE, 19144 215-754-0240 | MMT induction & Vivitrol | IOP / OP English |
| **MERAKEY BEHAVIORAL HEALTH**
4806 FRANKFORD AVE, 2ND FL, 19124 215-533-6204 | Vivitrol | IOP / OP; MH Tx on-site English |
| **MERAKEY BEHAVIORAL HEALTH**
11082 KNIGHTS ROAD, 19154 | Buprenorphine induction | IOP / OP English |
| **NORTHEAST COMMUNITY CNTR FOR BEHAVIORAL HEALTH**
4641 ROOSEVELT BLVD, 19124 215-831-2830 | MMT induction Vivitrol | IOP / OP English/ Spanish |
| **NORTH PHILA HEALTH SYSTEM - GOLDMAN CLINIC**
801 W. GIRARD AVE, 19122 215-787-2000 | MMT induction | IOP / OP English/ Spanish |
| **NORTHEAST TREATMENT CENTERS (NET)**
499 N. 5TH ST, 19123 (215)451-7100 | Buprenorphine induction | IOP / OP; MH Tx on-site English |
| **NORTHEAST TREATMENT CENTERS (NET)**
2205 BRIDGE ST, 19137 (215)286-5490 | Buprenorphine induction MMT induction & Vivitrol | IOP / OP; MH Tx on-site English |
<table>
<thead>
<tr>
<th>Provider &amp; Contact Info</th>
<th>MAT</th>
<th>Additional Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>NORTHEAST TREATMENT CENTERS (NET)</td>
<td>Buprenorphine induction</td>
<td>IOP/ OP; MH Tx on-site</td>
</tr>
<tr>
<td>7520 STATE ROAD, 19136 (215)831-6024</td>
<td>MMT induction &amp; Vivitrol</td>
<td>English; child care on site</td>
</tr>
<tr>
<td>PATHWAYS TO HOUSING</td>
<td>Buprenorphine induction</td>
<td>*Center of Excellence</td>
</tr>
<tr>
<td>5201 OLD YORK ROAD, SUITE 108, 19141 (215)390-6187</td>
<td>Vivitrol</td>
<td>English/ Spanish; Housing Assistance</td>
</tr>
<tr>
<td>PATHWAYS TO RECOVERY (PHMC)</td>
<td>Vivitrol &amp; Buprenorphine MMT clinic coordination</td>
<td>Partial Hospital Program; MH Tx on-site</td>
</tr>
<tr>
<td>2301 EAST ALLEGHENY AVE, 19134 (215)731-2402</td>
<td></td>
<td>English/ Spanish</td>
</tr>
<tr>
<td>PENN MEDICINE PRESBYTERIAN MEDICAL CENTER</td>
<td>Buprenorphine induction</td>
<td>*Center of Excellence; IOP/ OP</td>
</tr>
<tr>
<td>3910 POWELTON AVE, 5TH FL, 19104 (215662-8742</td>
<td>Vivitrol</td>
<td>English/ Spanish</td>
</tr>
<tr>
<td>PENN MEDICINE MOTHERS MATTER PROGRAM</td>
<td>Buprenorphine induction</td>
<td>*Center of Excellence; Pregnant Women</td>
</tr>
<tr>
<td>3400 SPRUCE ST, 1 WEST GATES, 19104 (215)573-8882</td>
<td></td>
<td>English</td>
</tr>
<tr>
<td>PHMC CARE CLINIC MAT PROGRAM</td>
<td>Buprenorphine induction</td>
<td>*Center of Excellence; Health Care Center</td>
</tr>
<tr>
<td>1200 CALLOWHILL ST, 1st Floor, 19123 267-398-0247</td>
<td>Vivitrol</td>
<td>English/ Spanish; PCP</td>
</tr>
<tr>
<td>PREVENTION POINT</td>
<td>Buprenorphine induction</td>
<td>*Center of Excellence; Harm Reduction Svcs</td>
</tr>
<tr>
<td>2913-2915 KENSINGTON AVE, 19134</td>
<td>Vivitrol</td>
<td>English/ Spanish</td>
</tr>
<tr>
<td>PROJECT HOME</td>
<td>Buprenorphine induction</td>
<td>*Center of Excellence; Housing Assistance</td>
</tr>
<tr>
<td>1515 FAIRMOUNT AVE, 19104 (215)320-6187 x5756</td>
<td>Vivitrol</td>
<td>English</td>
</tr>
<tr>
<td>SOAR CORP</td>
<td>MMT induction</td>
<td>OP</td>
</tr>
<tr>
<td>9150 MARSHALL ST, SUITE 2, 19114 (215)464-4450</td>
<td></td>
<td>English</td>
</tr>
<tr>
<td>THOMAS JEFFERSON UNIVERSITY FAMILY CENTER</td>
<td>MMT induction</td>
<td>*Center of Excellence (MATER); IOP/ OP; MH Tx on-site</td>
</tr>
<tr>
<td>1233 LOCUST ST, SUITE 201, 19107 (215)955-8577</td>
<td></td>
<td>Females only, pregnancy, child care on site; English</td>
</tr>
<tr>
<td>THOMAS JEFFERSON UNIVERSITY (NARP)</td>
<td>MMT induction</td>
<td>*Center of Excellence; IOP/ OP; MH Tx on-site</td>
</tr>
<tr>
<td>21st &amp; WASHINGTON AVE, 19147 (215)735-5979</td>
<td></td>
<td>English/ Spanish</td>
</tr>
<tr>
<td>TEMPLE TWO Program</td>
<td>Buprenorphine induction</td>
<td>*Center of Excellence, partners with the Wedge MC</td>
</tr>
<tr>
<td>3401 N BROAD ST, 19140 (215)707-3008</td>
<td></td>
<td>OB- GYN Svcs</td>
</tr>
<tr>
<td>WEDGE MEDICAL CENTER</td>
<td>Buprenorphine induction</td>
<td>*Center of Excellence, partners with Temple TWO</td>
</tr>
<tr>
<td>3609 N. BROAD ST, 19140 (215)223-1100</td>
<td>Vivitrol</td>
<td>English/ Spanish; IOP/ OP; MH Tx on-site</td>
</tr>
<tr>
<td>WEDGE MEDICAL CENTER</td>
<td>Buprenorphine induction</td>
<td>*Center of Excellence, partners with Temple TWO</td>
</tr>
<tr>
<td>2009 S. BROAD ST, 19148 (215)271-2200</td>
<td>Vivitrol</td>
<td>English; IOP/ OP; MH Tx on-site</td>
</tr>
<tr>
<td>WEDGE MEDICAL CENTER</td>
<td>Buprenorphine induction</td>
<td>*Center of Excellence, partners with Temple TWO</td>
</tr>
<tr>
<td>4243 FRANKFORD AVE, 19124 (215)744-3600</td>
<td>Vivitrol</td>
<td>English; IOP/ OP; MH Tx on-site</td>
</tr>
</tbody>
</table>

Call 1-888-545-2600 to speak to a service representative and access treatment.